| Name | Title | Contact Details |
|---|
Manhattan School of Music (MSM) is a renowned private music conservatory located in New York City, founded in 1917-1918 by pianist and philanthropist Janet D. Schenck. Originally established as the Neighborhood Music School in East Harlem, MSM has built a strong reputation for excellence in music education, influenced by notable artists like Pablo Casals and Harold Bauer. The school offers a range of academic programs, including Bachelor of Music, Master of Music, and Doctor of Musical Arts degrees. MSM specializes in classical and jazz performance, composition, conducting, and music education, and features a prominent opera program. Its campus in Morningside Heights includes instructional spaces, performance venues, and a residence hall, with facilities like the Hubbard Recital Hall, which houses a distinguished Aeolian-Skinner organ. MSM attracts a diverse student body of aspiring professional musicians from around the world, providing rigorous training and numerous performance opportunities. The institution is dedicated to fostering professional musicianship in both classical and jazz traditions.
Bridgewater Bank is a full-service financial institution based in St. Louis Park, Minnesota, founded in 2005. As a subsidiary of Bridgewater Bancshares, Inc., it is one of the largest locally-led banks in the state, with total assets of approximately $5.14 billion and nine branches across the Twin Cities area. The bank focuses on providing personalized, relationship-driven banking experiences for entrepreneurs, business professionals, and individuals. Its offerings include commercial banking services such as real estate lending, construction financing, and treasury management, as well as personal banking products like checking and savings accounts, loans, and certificates of deposit. Bridgewater Bank is committed to supporting its clients with tailored financial solutions and a strong emphasis on community connection.
GEICO is a Maryland-based financial institution that provides personal and commercial insurance products for individuals and businesses.
Electrify America, LLC is a prominent electric vehicle (EV) charging network in the United States, established in 2016 as a subsidiary of Volkswagen Group of America. The company aims to promote Zero-Emission Vehicle (ZEV) adoption by creating a nationwide network of ultra-fast and convenient EV charging stations. As of August 2024, Electrify America operates over 950 charging stations with more than 4,250 DC fast charging connectors, making it the largest open DC fast-charging network in the country. The company focuses on providing reliable and accessible hyper-fast charging solutions, supporting multiple connector types, including CCS and CHAdeMO, with plans to add Tesla’s North American Charging Standard (NACS) connectors in 2025. Electrify America is committed to sustainability, ensuring that all energy supplied to drivers is backed by 100% renewable energy certificates, and aims for a net zero carbon footprint. Headquartered in Reston, Virginia, the company employs around 300 people and actively engages in community education to promote equitable electrification.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.